Zoledronic Acid
Intravenous bisphosphonate for osteoporosis and bone metastases
Zoledronic acid is a highly potent nitrogen containing bisphosphonate administered intravenously and is one of the strongest inhibitors of osteoclastic bone resorption. Novartis introduced the substance in 2000 under the brand name Zometa for oncology indications; Aclasta followed in 2005 for osteoporosis. Numerous generics are available in Germany. Depending on the indication, the dose lies between 4 and 5 mg, with a dosing interval ranging from monthly (oncology) to once yearly (postmenopausal osteoporosis).
Yearly dosing in osteoporosis has remarkable clinical relevance. The HORIZON Pivotal Fracture Trial showed that 5 mg zoledronic acid per year over three years reduced vertebral fractures by 70 percent and hip fractures by 41 percent compared with placebo. Alongside denosumab, zoledronic acid is therefore the standard for patients with high fracture risk or with problems taking oral bisphosphonates.
Mechanism of Action
Bisphosphonates accumulate in the bone matrix through their high affinity for hydroxyapatite. During the next phase of osteoclastic resorption they are taken up by osteoclasts. In the osteoclast cytosol, zoledronic acid inhibits farnesyl pyrophosphate synthase, a key enzyme of the mevalonate pathway. As a result, prenylation of small GTPases (Ras, Rho, Rac) is blocked, the cell anchor collapses and osteoclasts undergo apoptosis.
Bone resorption is strongly reduced, bone mass and mineralisation increase, and fracture risk falls. In malignant bone disease, inhibition of osteoclast activity also reduces the release of bone resorbing cytokines from the tumour bone interaction, which can relieve pain and prevent skeletal events.
After intravenous administration, zoledronic acid distributes rapidly through the body; most of it is deposited in bone within a few hours, and the rest is excreted unchanged via the kidneys. Blood half life is about 7 hours, while the residence time in bone extends over years to decades, producing lasting effects even after therapy ends.
Indications
- Postmenopausal osteoporosis with increased fracture risk, 5 mg once yearly
- Osteoporosis in men with increased fracture risk, 5 mg once yearly
- Glucocorticoid induced osteoporosis in long term therapy with prednisone equivalents above 7.5 mg per day
- Paget's disease of bone 5 mg once, often sufficient for years of remission in active Paget's disease
- Skeletal related events in solid tumours with bone metastases (breast, prostate, non small cell lung cancer)
- Multiple myeloma to reduce bone involvement and skeletal events
- Tumour induced hypercalcaemia as emergency therapy
Dosage and Administration
Osteoporosis and Paget's disease: 5 mg intravenously as an infusion over at least 15 minutes, once yearly. Oncology indications: 4 mg intravenously over at least 15 minutes, every 3 to 4 weeks. Tumour induced hypercalcaemia: 4 mg once.
Before the infusion, patients must be adequately hydrated (at least 500 ml fluid before and after administration) and serum creatinine and electrolytes must be checked. A slow infusion of at least 15 minutes is critical to avoid acute kidney injury. Vitamin D and calcium supplementation is standard; in osteoporosis, 1000 mg calcium and 800 to 1000 IU vitamin D daily are recommended.
Renal impairment: contraindicated at creatinine clearance below 35 ml/min (osteoporosis) or below 30 ml/min (oncology). In mild to moderate impairment in the oncology setting, reduce dose according to the summary of product characteristics. Hepatic impairment: no formal adjustment, data are limited.
Side Effects
Very common: flu like acute phase reaction in the first days after the infusion with fever, muscle and limb pain, headache, fatigue. These symptoms appear mainly after the first dose, usually subside with later infusions, and respond well to paracetamol or NSAIDs.
Common: hypocalcaemia, anaemia, nausea, vomiting, bone pain, arthralgia, conjunctivitis, rise in creatinine and urea.
Uncommon to rare: osteonecrosis of the jaw, atypical femoral fractures, severe renal dysfunction up to acute kidney injury, uveitis, episcleritis, atrial fibrillation (discussed in the HORIZON trial, causality not definitively established).
Medication related osteonecrosis of the jaw (MRONJ): the risk is substantially higher in high dose oncology therapy (4 mg monthly) than under yearly osteoporosis dosing. Risk factors are invasive dental procedures, poor oral hygiene, smoking and glucocorticoids. Dental check up before starting therapy is recommended.
Interactions
- Aminoglycosides, loop diuretics, vancomycin: additive risk of hypocalcaemia and nephrotoxicity
- Other bisphosphonates, denosumab: combination is not meaningful, additive antiresorptive effect uncertain in benefit and safety
- Thalidomide, bortezomib (in multiple myeloma): possible increased nephrotoxicity
- NSAIDs: can place additional strain on renal function
- Calcium or vitamin D deficiency: must be corrected before starting therapy, otherwise risk of severe hypocalcaemia with tetany, arrhythmia and seizures
Special Notes
Dental preparation: before starting therapy, dental rehabilitation with removal of decayed teeth, root canal treatment and denture adjustment should be performed. During therapy, avoid invasive procedures (extraction, implants) where possible or perform them under antibiotic prophylaxis. Inform all dentists and oral surgeons about the bisphosphonate therapy.
Atypical femoral fractures: rare spontaneous or low trauma diaphyseal femoral fractures have been reported during long term antiresorptive therapy. Prodromal symptoms such as bilateral thigh pain should be taken seriously and evaluated with imaging.
Treatment holiday: in postmenopausal osteoporosis, a pause after 3 to 6 years of therapy is debated to reduce the risk of atypical fractures and jaw osteonecrosis. The decision depends on baseline risk, bone density and individual benefit risk assessment.
Pregnancy and breastfeeding: zoledronic acid is contraindicated. The substance remains in bone for years and can be released during a later pregnancy. Women of childbearing potential must use reliable contraception. Use in breastfeeding is not recommended.
Monitoring: creatinine and electrolytes (calcium, phosphate, magnesium) before each infusion; yearly bone density (DXA) in osteoporosis; dental check ups; symptom review for jaw problems and thigh pain.
You might also be interested in
- Ibandronic acid, oral or intravenous bisphosphonate
- Teriparatide, anabolic osteoporosis drug
- Leuprorelin, GnRH analogue in oncology
- Enzalutamide, androgen receptor inhibitor in prostate cancer
- Letrozole, aromatase inhibitor in breast cancer
Frequently Asked Questions
Why the flu like symptoms after the infusion?
The acute phase reaction is a typical side effect of nitrogen containing bisphosphonates. It arises from transient activation of the immune system and occurs especially after the first dose. Paracetamol works well prophylactically or for symptoms, along with ample fluids and physical rest. With later infusions the symptoms are typically much milder or absent.
How long does one yearly infusion last?
Zoledronic acid binds very firmly in bone and acts over at least 12 months. Fracture risk reduction persists 1 to 2 years after 3 to 6 years of therapy, which is considered in the drug holiday approach. Drug residues remain detectable in bone for years to decades.
Can I have dental surgery on zoledronic acid?
Yes, but with special care. Before planned dental surgery, coordination with your GP and dentist is important. At osteoporosis doses the MRONJ risk is low, in oncology long term therapy it is considerably higher. Prophylactic antibiotics, gentle surgical technique and close healing follow up are recommended.
Can I combine zoledronic acid with denosumab?
No, that is clinically not meaningful. Both substances inhibit bone resorption, and the combination raises side effects without additional benefit. Switching between the two is possible but should be well planned and monitored to avoid rebound after denosumab withdrawal.
Sources
- EMA, Aclasta (Zoledronic Acid) EPAR
- AWMF, S3 Guideline Osteoporosis (DVO) and oncology guidelines
- Gelbe Liste, Zoledronic Acid active substance profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace consultation with a licensed physician or pharmacist. Medicines should only be taken on medical prescription or via a pharmacy. All information is based on product information and recognised scientific sources published at the time of creation; the manufacturer's current summary of product characteristics is always authoritative. Sanoliste assumes no liability for the completeness, timeliness or accuracy of the information presented. In a medical emergency, call the emergency number 112 (Europe).